Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: Results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations

Current Medical Research and Opinion

Volumn 31, Issue 7, 2015, Pages 1413-1429

  Ueberall, Michael A ^a   Mueller Schwefe, Gerhard H H ^b  

^a Institute for Neurological Sciences   (Germany)

^b Interdisciplinary Pain and Palliative Care Center   (Germany)

Author keywords

Bowel function; Chronic pain; Constipation; Naloxone; Oxycodone; PROBE; Quality of life

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LAXATIVE; MORPHINE; MUSCLE RELAXANT AGENT; NALOXONE PLUS OXYCODONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; ASSESSMENT OF HUMANS; BOWEL FUNCTION INDEX; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; INTESTINE FUNCTION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OPIOID INDUCED CONSTIPATION; OUTCOME ASSESSMENT; PAIN INTENSITY; PATIENT SATISFACTION; PHYSICAL DISABILITY; PRESCRIPTION; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOMNOLENCE; TREATMENT DURATION; VISUAL ANALOG SCALE; CHEMICALLY INDUCED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANALGESICS, OPIOID; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; GERMANY; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; MORPHINE; NALOXONE; OXYCODONE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84934274614     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1047747     Document Type: Article

References (44)

1. Breivik H, Collett B, Ventafridda V. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333
2. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449-62
3. Sng BL, Schug SA. The role of opioids in managing chronic non-cancer pain. Ann Acad Med Singapore 2009; 38: 960-6
4. Wiffen PJ. Evidence-based pain management and palliative care in issue one for 2005 of The Cochrane Library. J Pain Palliat Care Pharmacother 2005; 19: 65-8
5. Caraceni A, Hanks G, Kaasa S, et al., European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68
6. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, activecontrolled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26: 50-60
7. Chou R, Huffman LH, American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147: 505-14
8. Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A, National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician 2011; 57: 1257-66
9. Häuser W, Bock F, Engeser P, et al. S3 guideline for the long-Term use of opioids in non-cancer pain. Dtsch Arztebl Int 2014; 111: 732-40
10. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11-18S
11. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005; 71: 425-33
12. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009; 10: 35-42
13. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71
14. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007; 34: 547-65
15. Panchal SJ, Mueller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61: 1181-7
16. Odegard PS, Burke C. Managements of opioid induced constipation in elderly patients. Consultant Pharmacist 1996; 11: 17-22
17. Leppert W. The role of opioid receptor antagonists in the treatment of opioidinduced constipation: a review. Adv Ther 2010; 27: 714-30
18. Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013; 22: 161-6
19. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 56-64
20. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-To-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531-43
21. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/ severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010; 10: 1-9
22. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-54
23. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-Term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010; 64: 1-12
24. Ahmedzai SH, Leppert W, Janecki M, et al. Long-Term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-Tosevere chronic cancer pain. Support Care Cancer 2015; 23: 823-30
25. Blagden M, Hafer J, Duerr H, et al. Long-Term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-To-severe chronic pain: pooled analysis of extension phases of two phase III trials. Neurogastroenterol Motil 2014; 26: 1792-801
26. Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010; 26: 1377-87
27. Kassenärztliche Bundesvereinigung, Arzneimittelkommission der Deutschen Ärzteschaft. Oxycodon/Naloxon. Wirkstoff Aktuell 2012; 6
28. Böger RH, Schmidt G. Analgetika. In: Schwabe U, Paffrath D (eds.): Arzneiverordnungsreport 2014. Berlin, Heidelberg, Springer: 2014: 301-19
29. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded endpoint (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1: 113-19
30. Cryer B, Li C, Simon LS, et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013; 108: 392-400
31. Deutsche Schmerzgesellschaft. Deutscher Schmerzfragebogen [German pain questionnaire]. Available at: http://www.dgss.org/deutscher-schmerzfragebogen [Last accessed 10 April 2015]
32. Deutsche Schmerzgesellschaft. Handbuch zum Deutschen Schmerzfragebogen [Manual for the German pain questionnaire]. Available at: http://www.dgss.org/fileadmin/pdf/12-DSF-Manual-2012.2.pdf [Last accessed 10 April 2015]
33. Rentz AM, Yu R, Mueller-Lissner S, Leyendecker P. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371-83
34. Ueberall MA, Mueller-Lissner S, Buschmann-Kramm C, Bosse B. The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011; 39: 41-50
35. Frettlöh J, Maier C, Gockel H, Hüppe M. Validation of the German Mainz Pain Staging System in different pain syndromes. Schmerz 2003; 17: 240-51
36. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992; 50: 133-49
37. Poelaert J, Koopmans-Klein G, Dioh A, et al. Treatment with prolongedrelease oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther 2015; 37: 784-92
38. Levine JD, Gordon NC, Fields HL. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 1979; 278: 740-1
39. Rochford J, Stewart J. Activation and expression of endogenous pain control mechanisms in rats given repeated nociceptive tests under the influence of naloxone. Behav Neurosci 1987; 101: 87-103
40. Greeley J, Le AD, Poulos CX, Cappel H. 'Paradoxical' analgesia induced by naloxone and naltrexone. Psychopharmacology 1988; 96: 36-9
41. Poulos CX, Knoke DM, Le AD, Cappell H. Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing. Psychopharmacology 1990; 100: 31-5
42. Wang H-Y, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in muopioid receptor - G protein coupling and Gbg signaling. Neuroscience 2005; 135: 247-61
43. Burns L, Wang H-Y. Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach. Clinical Medicine Insights: Therapeutics 2010; 2: 857-68
44. Kohro T, Yamazaki T. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. Hypertens Res 2009; 32: 109-14